Sign up for our Weekly Checkup Newsletter
Back to News
Insights · News

Golden Gate Capital to take control of Recuro Health, Massachusetts filing shows

Golden Gate Capital has agreed to acquire Recuro Health, the virtual-first care company founded by Teladoc co-founder Michael Gorton, according to a Massachusetts Health Policy Commission filing. No price was disclosed.

3 min read

Golden Gate Capital has agreed to acquire Recuro Health, the Texas virtual-first care company founded by Teladoc co-founder Michael Gorton, according to a material change notice filed with the Massachusetts Health Policy Commission. The notice is dated October 16, 2026 and appeared on the commission's transaction list on October 23. Neither Recuro nor Golden Gate has announced the deal.

What the filing says

Recuro Health, Inc. will merge with an acquisition entity and survive as a wholly owned subsidiary of RecHealth Intermediate, LLC, a vehicle the filing says is indirectly owned by funds associated with Golden Gate Capital. The stated purpose of the transaction is "to effect a change of control of the Company."

Recuro's existing securityholders will receive cash for their shares. Some will retain an ongoing equity interest in the buyer's parent, and a portion of the consideration is contingent on Recuro's future financial performance. No dollar figures are given. The proposed effective date is December 31, 2026, and the parties say they also intend to file material change notices in California and Indiana.

Recuro's Massachusetts footprint runs through its management services organization, Wellspring Telehealth, LLC, which does business as WellVia and manages Wellspring Physician P.C. of Massachusetts under a management services agreement. The affiliated professional corporations provide virtual primary care, urgent care and behavioral health. The company told the commission it does not expect the transaction to change reimbursement rates, referral patterns, access or quality of care and that it will continue to operate in the ordinary course.

The company

Recuro describes itself as an integrated digital health company. Its platform, which it has marketed as a "Digital Medical Home," combines virtual primary care, behavioral health and urgent care with pharmacy, care management and advocacy benefits sold to employers and other plan sponsors rather than directly to consumers. The company was formed in 2021 and is based in the Dallas area; its chief executive, Michael Gorton, was a co-founder of Teladoc.

Recuro assembled much of its platform through acquisitions in its first two years. Scope Research's database records seven: UDoTest and SupDoc in May 2021, Family Care Path and the Legacy decision-support app in June 2021, MyLifeIQ in September 2021, WellVia in April 2022 and Competitive Health in August 2022. The WellVia purchase is the source of the telehealth MSO named in the Massachusetts filing. On the funding side, the company raised a $15 million Series A led by ARCH Venture Partners in 2021 and a $47 million Series B in April 2023 with participation from ARCH, Flippen Group, GPG Ventures and 4D Capital.

Golden Gate's return to provider services

San Francisco-based Golden Gate Capital has been a periodic rather than constant healthcare buyer. Its two most recent healthcare platforms in Scope's records both date from 2019: a majority stake in Ensemble Health Partners, the revenue cycle company in which it later sold a majority to Warburg Pincus and Berkshire Partners, and Invo HealthCare Associates, the pediatric behavioral health provider that was folded into The Stepping Stones Group in January 2026. Recuro would be the firm's first virtual care investment and its first new healthcare platform tracked by Scope since then.

The structure described in the notice, cash to existing holders with partial rollover and a performance-based component, is one that has become common in sales of venture-backed digital health companies to control buyers over the past two years. The filing does not say what share of the consideration is contingent or what targets it is tied to.

What to watch

The HPC's 30-day window to decide on a cost and market impact review runs into mid-November. The California notice, if filed under the Office of Health Care Affordability's material change program, will be posted on the OHCA list and may carry more detail on the parties. Recuro's employer customers and its payer partners have not been named in the filing.

Source: Notice of Material Change, Recuro Health, Inc. and Golden Gate Capital, Massachusetts Health Policy Commission, dated October 16, 2026 (https://masshpc.gov/sites/default/files/2026-10/20261016_Recuro-GSC_MCN.pdf). Funding history from Recuro's announcements as reported by Dallas Innovates (https://dallasinnovates.com/recuro-health-secures-47m-in-series-b-funding-for-its-digital-medical-home/). Acquisition history from the Scope Research healthcare M&A database.